Skip to main content

Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma.

Publication ,  Journal Article
Parrott, TD; Wallace, MD; Niehoff, KM; Eble, SH; Blumenfeld, L; Sevin, CM; Choma, NN; Gao, Y; Choi, L; Lindsell, CJ; Zuckerman, AD
Published in: J Am Coll Clin Pharm
December 2023

INTRODUCTION: Patients with asthma and chronic obstructive pulmonary disease rely on inhaler therapy to reduce disease progression and exacerbation risk. Patients admitted to the hospital are at an increased risk for exacerbations and readmission if their inhaler therapy upon discharge is not aligned with current guidelines and/or affordable. OBJECTIVE: Assess the appropriateness of the chronic inhaler regimen for patients admitted to the hospital based on clinical practice guidelines and insurance coverage. METHODS: A sub-study was designed to analyze a cohort of a single-center, pragmatic, prospective randomized controlled trial at a large academic medical center. Patients admitted to a medicine service with a pharmacist and prescribed a long-acting inhaler were included. Participants randomized to a pharmacist-led intervention were assessed for inhaler appropriateness based on clinical guidelines and patient insurance. The objective of this sub-study is to assess the number of inhalers identified as inappropriate based on the pharmacist's review. A patient was considered to have an inappropriate inhaler regimen if any of their inhalers were inconsistent with guideline recommendations or not covered by insurance. Descriptive statistics were used to characterize appropriate inhaler use. RESULTS: The study pharmacist reviewed 552 unique inhalers for 348 patients. Overall, 42% of inhalers were inappropriate, affecting 50.3% of participants. 20% of inhalers were inappropriate based on insurance, 26% were inappropriate based on guidelines, and 7% were inappropriate based on both criteria. Recommendations were placed via a pharmacy consult for 198 patients (57%), most recommending an inhaler initiation (55%), followed by inhaler discontinuation (38%). CONCLUSION: A pharmacist-led review of chronic inhaler therapy for patients admitted to the hospital identified the need for a change in therapy based on financial or clinical guidelines in over half of the patients reviewed. Interventions to increase the appropriateness of prescribed inhalers are needed to reduce disease progression and disease exacerbation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Clin Pharm

DOI

EISSN

2574-9870

Publication Date

December 2023

Volume

6

Issue

12

Start / End Page

1304 / 1312

Location

United States
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Parrott, T. D., Wallace, M. D., Niehoff, K. M., Eble, S. H., Blumenfeld, L., Sevin, C. M., … Zuckerman, A. D. (2023). Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma. J Am Coll Clin Pharm, 6(12), 1304–1312. https://doi.org/10.1002/jac5.1862
Parrott, Tate D., Matthew D. Wallace, Kristina M. Niehoff, Sarah H. Eble, Lauren Blumenfeld, Carla M. Sevin, Neesha N. Choma, et al. “Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma.J Am Coll Clin Pharm 6, no. 12 (December 2023): 1304–12. https://doi.org/10.1002/jac5.1862.
Parrott TD, Wallace MD, Niehoff KM, Eble SH, Blumenfeld L, Sevin CM, et al. Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma. J Am Coll Clin Pharm. 2023 Dec;6(12):1304–12.
Parrott, Tate D., et al. “Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma.J Am Coll Clin Pharm, vol. 6, no. 12, Dec. 2023, pp. 1304–12. Pubmed, doi:10.1002/jac5.1862.
Parrott TD, Wallace MD, Niehoff KM, Eble SH, Blumenfeld L, Sevin CM, Choma NN, Gao Y, Choi L, Lindsell CJ, Zuckerman AD. Pharmacist Review of Chronic Inhaler Therapy Appropriateness for Hospitalized Patients with COPD or Asthma. J Am Coll Clin Pharm. 2023 Dec;6(12):1304–1312.

Published In

J Am Coll Clin Pharm

DOI

EISSN

2574-9870

Publication Date

December 2023

Volume

6

Issue

12

Start / End Page

1304 / 1312

Location

United States